Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 5/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
| ▸ | PDE6A | P16499 | 1/20 | 0.36 |
| ▸ | PDE6G | P18545 | 1/20 | 0.36 |
| ▸ | PDE6B | P35913 | 1/20 | 0.36 |
| ▸ | PDE6C | P51160 | 1/20 | 0.36 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526795 | 0.87 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP17A1PDE2APDE10A | |
| SCHEMBL10021504 | 0.76 | PDE4A (0.48) | PDE5AGAAMAPTTSHRMAPK1 | |
| SCHEMBL10272835 | 0.76 | CYP17A1 (0.58) | CYP11B1CYP11B2CYP17A1PDE2APDE10A | |
| SCHEMBL527730 | 0.70 | CYP17A1 (0.51) | CYP11B1CYP11B2CYP17A1PDE2APDE10A | |
| SCHEMBL526484 | 0.69 | KDM4E (0.45) | CYP11B1CYP11B2CYP17A1ABL1GAA | |
| SCHEMBL1770449 | 0.69 | CYP11B1 (0.45) | CYP11B1CYP11B2GAATSHRCYP1A2 | |
| SCHEMBL29829964 | 0.69 | CYP11B1 (0.49) | CYP11B1CYP11B2GAATSHRCYP1A2 | |
| SCHEMBL5114144 | 0.69 | CYP11B1 (0.49) | CYP11B1CYP11B2GAATSHRCYP1A2 | |
| SCHEMBL18262925 | 0.68 | AURKA (0.45) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL12626305 | 0.68 | PDE4A (0.47) | PDE5AGAAMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | CYP11B1 22/4885CYP11B2 38/4885CYP17A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.